Citadel Advisors’s HilleVax HLVX Stock Holding History

Citadel Advisors’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,196	Closed	-$60.1K	–	13336
2025 Q2	$60.1K	Buy	+30,196	New	+$55.2K	﹤0.01%	11677
2025 Q1	–	Sell	-118,400	Closed	-$245K	–	14927
2024 Q4	$245K	Sell	118,400 -57,067	-33%	-$107K	﹤0.01%	10076
2024 Q3	$309K	Sell	175,467 -356,352	-67%	-$914K	﹤0.01%	9287
2024 Q2	$7.69M	Sell	531,819 -117,557	-18%	-$1.62M	﹤0.01%	3141
2024 Q1	$10.8M	Sell	649,376 -75,000	-10%	-$1.2M	﹤0.01%	2851
2023 Q4	$11.6M	Sell	724,376 -142,837	-16%	-$1.9M	﹤0.01%	2643
2023 Q3	$11.7M	Buy	+867,213	New	+$12.2M	﹤0.01%	2490

Citadel Advisors's HLVX Position: Q3 2025 in Review

Citadel Advisors sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 30,196 shares — an estimated $60.1K sold.

Citadel Advisors first reported a position in HLVX in Q3 2023 and held it in 7 quarters. The position peaked at $11.7M in Q3 2023. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.

Citadel Advisors reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 30,196 HilleVax shares in Q3 2025, an estimated $60.1K.
Citadel Advisors first reported a position in HilleVax in Q3 2023 and held it in 7 quarters.
Citadel Advisors's HilleVax position peaked at $11.7M in Q3 2023.
1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.